System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tamar Tadmor is an expert in Hematology at Bnai Zion Medical Center (Israel). As of October 2026, ScienceLeadR ranks Tamar Tadmor in the top 1% of experts worldwide for Lymphoproliferative Disorders, Leukemia and Lymphoma. Tamar Tadmor has authored 311 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 2 of them ongoing. SLR score: 1,356 (community average: 125). How the SLR is computed.

LeadR Profile

Tamar Tadmor Bnai Zion Medical Center Israel
1 356 ScienceLeadR Reputation 1356

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Bnai Zion Medical Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 311

Citations

Citations: 6 395 1st author: 80 Last author: 51 Unique author: 11

Main journals

Blood 74
Leuk Lymphoma 54
Acta Haematol 15
Am J Hematol 12
Br J Haematol 12

Best Journals

N Engl J Med 6
J Clin Oncol 1
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Response to two comments on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation" by S. Molica and A. Tedeschi: Beyond the binary choice.
PMID 42852072 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid		Hemasphere20260
Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.
PMID 42837320 — hematology, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, lymph, therapeutics, telomere		Blood20260
Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.
PMID 42613996 — cells, lymphoma, b-cell, ecotype, lymphoma, lymphoma, large b-cell, diffuse, classification, mutation, b-lymphocytes, immune evasion		Clin Transl Med20260
Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.
PMID 42573556 — hematology, therapeutics		Am J Hematol20260
Bringing the hospital home: exploring the challenges and perspectives of healthcare professionals on home treatment in hemato-oncology: a qualitative analysis.
PMID 42489784 — nurses, hematology, safety, physicians, therapeutics, palliative care		Support Care Cancer20260

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 9
N/A 6
Phase 2 3

By status:

Completed 12
Active not recruiting 2
Unknown 2
Not yet recruiting 1
Recruiting 1

By type:

Interventional 15
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 0
multicentricup10 12

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Familial B cell Lymphoproliferative Disorders
NCT05718986 — cells, epidemiology, lymphocytosis, leukemia, lymphocytic, chronic, b-cell, precancerous conditions, leukemia, leukemia, lymphoid, lymphoproliferative disorders, b-lymphocytes		N/ANot yet recruiting2024
Ibrutinib Monotherapy Versus Fixed duration Venetoclax Plus Obinutuzumab Versus Fixed duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318 — cells, leukemia, leukemia, lymphoid, b-lymphocytes, leukemia, b-cell		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS